Log on / register
BioMed Central home | Journals A-Z | Feedback | Support | My details
Open AccessCase report

Procalcitonin serum levels in tertian malaria

Christoph Manegold email, Stefan Schmiedel email, Collins B Chiwakata email and Manfred Dietrich email

Bernhard Nocht Institute for Tropical Medicine Bernhard-Nocht-Str. 74 20359 Hamburg Germany

author email corresponding author email

Malaria Journal 2003, 2:34doi:10.1186/1475-2875-2-34

Published: 16 October 2003

Abstract

Background

Procalcitonin (PCT) is closely correlated with parasite burden and clinical outcome in falciparum malaria. The role of PCT in tertian malaria has not previously been investigated.

Patients and methods

PCT serum levels in 37 patients with tertian malaria were analysed. Clinical and laboratory parameters were assessed and statistically correlated both to the initial PCT levels and during the course of the disease.

Results

PCT levels rose for one day after commencing treatment and declined thereafter. However, there was no significant correlation with parasite burden, clinical parameters, laboratory values, or the presence of semi-immunity. Before treatment, the majority of patients showed normal or slightly elevated PCT levels (< 2.5 ng/ml), but PCT was markedly elevated (4.8 – 47 ng/ml) in one third of the population. The two groups did not differ by any other of the assessed parameters. Thus, while the post-treatment course of PCT resembles falciparum malaria, the lack of correlation between disease severity and even high PCT levels in a large proportion of patients is intriguing.

Conclusions

There is a fundamental difference in the relationship of PCT with tertian malaria not seen in other infectious diseases in which elevated PCT levels have been observed. This suggests distinct pathophysiological pathways in malaria.


© 1999-2010 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.